Anubis Bio
Patented Microbiome-Cleanser (TM) food platform that quickly resolves distress diarrhea in animals.
Patented Microbiome-Cleanser (TM) food platform that quickly resolves distress diarrhea in animals.
Anubis Bio is a biotechnology startup that has developed a patented Microbiome-Cleanser (TM) food platform aimed at resolving distress diarrhea in animals. The company, founded in 2018 and headquartered in the United States, focuses on strengthening and supporting animal immune and gastrointestinal systems, with a primary focus on dogs through their website www.doggystat.com. Anubis Bio has made significant strides in the market, securing two major B2B distribution partnerships in Q1 '21. The startup successfully raised a $1.00M Seed Round investment on 20 March 2020, with the backing of prominent investors including Life Science Angels and Freada Kapor Klein. Anubis Bio's innovative approach to addressing gastrointestinal distress in animals, coupled with its strong investor support and strategic partnerships, positions the company for significant growth and impact within the biotechnology, healthcare, and nutrition industries.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Seed Round | $1.00M | 2 |
|
20 Mar 2020 |
| Seed Round | Unknown | 1 |
|
07 Jun 2019 |
| Series A | $40.00K | 1 |
|
19 Mar 2019 |
| Angel Round | Unknown | 2 |
|
01 Jun 2018 |
No recent news or press coverage available for Anubis Bio.
We care about your data, and we'd love to use cookies make your experience better.
